Cargando…

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir

BACKGROUND AND AIM: Loss of hepatitis B surface antigen (HBsAg) is an important goal in the treatment of chronic hepatitis B. We investigated whether switching from long‐term entecavir (ETV) administration to tenofovir (TFV) (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF]) could...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamaki, Nobuharu, Kurosaki, Masayuki, Kirino, Sakura, Yamashita, Koji, Osawa, Leona, Sekiguchi, Shuhei, Hayakawa, Yuka, Wang, Wan, Okada, Mao, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Yasui, Yutaka, Tsuchiya, Kaoru, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Enomoto, Nobuyuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273717/
https://www.ncbi.nlm.nih.gov/pubmed/32514449
http://dx.doi.org/10.1002/jgh3.12273
_version_ 1783542460850372608
author Tamaki, Nobuharu
Kurosaki, Masayuki
Kirino, Sakura
Yamashita, Koji
Osawa, Leona
Sekiguchi, Shuhei
Hayakawa, Yuka
Wang, Wan
Okada, Mao
Higuchi, Mayu
Takaura, Kenta
Maeyashiki, Chiaki
Kaneko, Shun
Yasui, Yutaka
Tsuchiya, Kaoru
Nakanishi, Hiroyuki
Itakura, Jun
Takahashi, Yuka
Enomoto, Nobuyuki
Izumi, Namiki
author_facet Tamaki, Nobuharu
Kurosaki, Masayuki
Kirino, Sakura
Yamashita, Koji
Osawa, Leona
Sekiguchi, Shuhei
Hayakawa, Yuka
Wang, Wan
Okada, Mao
Higuchi, Mayu
Takaura, Kenta
Maeyashiki, Chiaki
Kaneko, Shun
Yasui, Yutaka
Tsuchiya, Kaoru
Nakanishi, Hiroyuki
Itakura, Jun
Takahashi, Yuka
Enomoto, Nobuyuki
Izumi, Namiki
author_sort Tamaki, Nobuharu
collection PubMed
description BACKGROUND AND AIM: Loss of hepatitis B surface antigen (HBsAg) is an important goal in the treatment of chronic hepatitis B. We investigated whether switching from long‐term entecavir (ETV) administration to tenofovir (TFV) (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF]) could contribute to the reduction of HBsAg levels. METHODS: The degree of HBsAg reduction by 48 weeks in 30 patients following switching from ETV to TFV was compared with results from 147 patients who continued ETV as a control. RESULTS: TFV group switched to TFV after mean 6.79 years of ETV administration. HBV‐DNA levels remained below 1.0 log IU/mL in all cases in both groups during 48 weeks. Median HBsAg reduction at 48 weeks was 0.075 (−0.05 to 0.38) log/IU/mL in the TFV switch group, and 0.070 (−0.28 to 0.50) in the ETV continuation group, which was not statistically significant (p = 0.5). In a subgroup of hepatitis B e antigen negative patients whose HBsAg had not been reduced (HBsAg reduction ≤0 log IU/mL) in the 48 weeks prior to entry into the study, HBsAg reduction was significantly higher in the TFV switch group than in the ETV continuation group (0.15 [0.07–0.135] in TFV, 0.09 [−0.14 to 0.25] log IU/mL in ETV, p = 0.04). CONCLUSION: Although HBsAg reduction is equivalent with ETV continuation and switching to TFV in all patients at 48 weeks, switching from ETV to TFV could provide an alternative therapeutic strategy toward HBsAg elimination in a specific subpopulation of patients.
format Online
Article
Text
id pubmed-7273717
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-72737172020-06-07 Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir Tamaki, Nobuharu Kurosaki, Masayuki Kirino, Sakura Yamashita, Koji Osawa, Leona Sekiguchi, Shuhei Hayakawa, Yuka Wang, Wan Okada, Mao Higuchi, Mayu Takaura, Kenta Maeyashiki, Chiaki Kaneko, Shun Yasui, Yutaka Tsuchiya, Kaoru Nakanishi, Hiroyuki Itakura, Jun Takahashi, Yuka Enomoto, Nobuyuki Izumi, Namiki JGH Open Original Articles BACKGROUND AND AIM: Loss of hepatitis B surface antigen (HBsAg) is an important goal in the treatment of chronic hepatitis B. We investigated whether switching from long‐term entecavir (ETV) administration to tenofovir (TFV) (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF]) could contribute to the reduction of HBsAg levels. METHODS: The degree of HBsAg reduction by 48 weeks in 30 patients following switching from ETV to TFV was compared with results from 147 patients who continued ETV as a control. RESULTS: TFV group switched to TFV after mean 6.79 years of ETV administration. HBV‐DNA levels remained below 1.0 log IU/mL in all cases in both groups during 48 weeks. Median HBsAg reduction at 48 weeks was 0.075 (−0.05 to 0.38) log/IU/mL in the TFV switch group, and 0.070 (−0.28 to 0.50) in the ETV continuation group, which was not statistically significant (p = 0.5). In a subgroup of hepatitis B e antigen negative patients whose HBsAg had not been reduced (HBsAg reduction ≤0 log IU/mL) in the 48 weeks prior to entry into the study, HBsAg reduction was significantly higher in the TFV switch group than in the ETV continuation group (0.15 [0.07–0.135] in TFV, 0.09 [−0.14 to 0.25] log IU/mL in ETV, p = 0.04). CONCLUSION: Although HBsAg reduction is equivalent with ETV continuation and switching to TFV in all patients at 48 weeks, switching from ETV to TFV could provide an alternative therapeutic strategy toward HBsAg elimination in a specific subpopulation of patients. Wiley Publishing Asia Pty Ltd 2019-10-24 /pmc/articles/PMC7273717/ /pubmed/32514449 http://dx.doi.org/10.1002/jgh3.12273 Text en © 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Tamaki, Nobuharu
Kurosaki, Masayuki
Kirino, Sakura
Yamashita, Koji
Osawa, Leona
Sekiguchi, Shuhei
Hayakawa, Yuka
Wang, Wan
Okada, Mao
Higuchi, Mayu
Takaura, Kenta
Maeyashiki, Chiaki
Kaneko, Shun
Yasui, Yutaka
Tsuchiya, Kaoru
Nakanishi, Hiroyuki
Itakura, Jun
Takahashi, Yuka
Enomoto, Nobuyuki
Izumi, Namiki
Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
title Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
title_full Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
title_fullStr Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
title_full_unstemmed Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
title_short Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
title_sort hepatitis b surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273717/
https://www.ncbi.nlm.nih.gov/pubmed/32514449
http://dx.doi.org/10.1002/jgh3.12273
work_keys_str_mv AT tamakinobuharu hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT kurosakimasayuki hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT kirinosakura hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT yamashitakoji hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT osawaleona hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT sekiguchishuhei hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT hayakawayuka hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT wangwan hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT okadamao hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT higuchimayu hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT takaurakenta hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT maeyashikichiaki hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT kanekoshun hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT yasuiyutaka hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT tsuchiyakaoru hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT nakanishihiroyuki hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT itakurajun hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT takahashiyuka hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT enomotonobuyuki hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir
AT izuminamiki hepatitisbsurfaceantigenreductionasaresultofswitchingfromlongtermentecaviradministrationtotenofovir